These strong effects recommend S63845 for combination treatment with MAPK inhibitors, which may apply to approved BRAF inhibitors in BRAF-mutated melanomas, as well as to combinations of SCH772984/S63845 in both BRAF-mutated and BRAF-WT melanomas. This evidence concerns the gene BRAF and melanoma.